Redir

Thursday, July 1, 2010

The Leukemia & Lymphoma Society� and Avila Therapeutics" Enter Partnership to Accelerate Development of AVL-292 For Patients with B Cell Malignancies

The Leukemia & Lymphoma Society (LLS) and Avila Therapeutics, Inc., today announced they have established a collaboration to support development of one of Avila's lead product candidates, AVL-292, for treatment of adults with B cell cancers....
Read More...
[Source: Society News]

No comments:

Post a Comment